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Abstract
Background: Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo,
against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess the efficacy
and tolerability of olaparib, a PARP inhibitor, in patients with advanced Ewing sarcoma (EWS) progressing after prior
chemotherapy.
Methods: In this nonrandomized phase II trial, adult participants with radiographically measureable metastatic EWS
received olaparib tablets, 400 mg orally twice daily, until disease progression or drug intolerance. Tumor
measurements were determined by CT or MRI at 6 and 12 weeks after starting olaparib administration, and then
every 8 weeks thereafter. Tumor response determinations were made according to RECIST 1.1, and adverse event
determinations were made according to CTCAE, version 4.0. A total of 22 participants were planned to be enrolled
using a conventional 2-step phase II study design. If no objective responses were observed after 12 participants had
been followed for at least 3 months, further accrual would be stopped.
Results: 12 participants were enrolled, and all were evaluable. There were no objective responses (PR/CR), 4 SD
(duration 10.9, 11.4, 11.9, and 17.9 wks), and 8 PD as best response. Of the SD, 2 had minor responses (−9%
and −11.7% by RECIST 1.1). The median time to disease progression was 5.7 weeks. Further enrollment was
therefore discontinued. No significant or unexpected toxicities were observed with olaparib, with only a single
case each of grade 3 anemia and grade 3 thrombocytopenia observed.
Conclusions: This study is the first report of a prospective phase II trial to evaluate the safety and efficacy of a
PARP inhibitor in patients with advanced Ewing sarcoma after failure of standard chemotherapy. Olaparib
administration was safe and well tolerated when administered to this small heavily pre-treated cohort at the
400 mg BID dose, although the median duration of dosing was for only 5.7 weeks. No significant responses
or durable disease control was seen, and the short average interval to disease progression underscores the
aggressiveness of this disease. Other studies to combine cytotoxic chemotherapy with PARP inhibition in
EWS are actively ongoing.
Trial registration: ClinicalTrials.gov Identifier: NCT01583543
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Ewing sarcoma is a highly malignant tumor of either
bone or soft tissue that occurs most frequently in the
adolescent and young adult years [1]. The cell of origin
of Ewing sarcoma remains poorly defined, however a
neuroectodermal origin is suspected. Although a rare
disease, it is the 2nd most common primary bone
tumor of childhood. With the advent of adjuvant
chemotherapy, the prognosis of localized Ewing sar-
coma has improved from less than 20% to currently
greater than 70% survival in 5-years. However, patients
with recurrent Ewing sarcoma have poor prognosis
[2-5]. Few patients with recurrences become long-term
survivors, and they are usually limited to those with
local recurrence and a long initial remission [4,6,7].
Second line and subsequent chemotherapy has had
limited success and is associated with significant tox-
icity. There is no single accepted standard of care that
is highly effective for these patients, and complete
responses are rare. Five-year event-free and overall
survival following recurrence is less than 15% [3,5,8].
The prognosis is even worse for patients who relapse
within two years after diagnosis and patients who
have distant recurrences that are not treatable with
radical surgery. In a single institution longitudinal ex-
perience over 20 years, 215 patients of an initial cohort
of 402 patients (53.5%) relapsed. Of these relapsed
patients, 200 (93%) died with a mean survival of
13.1 months and no patient with extrapulmonary
metastases survived [8].
Garnett et al. observed that Ewing sarcoma cell lines
were over 100-fold more sensitive to PARP inhibition
with olaparib (AZD2281, KU-0059436), a potent Poly-
adenosine 5′diphophoribose (poly ADP ribose) poly-
merase (PARP) inhibitor, than were control cell lines,
and treatment with Olaparib selectively induced apop-
tosis [9]. This level of sensitivity was comparable to
that observed in BRCA2 deficient cells. Olaparib has
been shown to inhibit selected tumor cell lines in vitro
and in xenograft and primary explant models as well
as in genetic BRCA knock-out models, either as a
stand- alone treatment or in combination with estab-
lished chemotherapies [10-12]. Brenner et al. addition-
ally showed that PARP inhibition by olaparib potentiated
DNA damage induced by expression of EWS-FLI1 or
EWS-ERG fusion genes, thereby inhibiting growth of
tumor subcutaneously implanted into SCID mice [13].
Based on these results, we performed a single arm
open labeled clinical trial, constructed along a conven-
tional Simon 2-step phase II study design [14], to
evaluate the safety and clinical activity of olaparib in
adult patients with advanced Ewing sarcoma following
failure of conventional chemotherapy. (ClinicalTrials.
gov Identifier: NCT01583543).
Methods
This study is a single arm, open label, phase II study to
investigate the clinical efficacy and safety of olaparib
in patients with metastatic and/or recurrent Ewing
sarcoma. Pathologic diagnosis of Ewing sarcoma had
to be confirmed by pathologic review at one of the
participating institutions, but molecular testing for an
EWS translocation was not required for eligibility.
A single consortium, the Dana-Farber/Harvard Cancer
Center completed the study through two active sites
Table 1 Baseline characteristics
Age (in years, at date of registration)
Mean 30.5
Std 15.38
Min 18
Max 70
Gender
Male N=10, 83%
Female N=2, 17%
Institution
DFCI N=4, 33.3%
MGH N=8, 66.7%
Performance status
0 N=6, 50%
1 N=6, 50%
Prior surgery
Yes N=9, 75%
No N=3, 25%
Prior radiation
Yes N=9, 75%
No N=3, 25%
Number of prior radiation treatments
N (patients) 9
Mean (#prior treatments) 1.7
Std 1.1
Median 1.0
Min 1
Max 4
Prior Chemotherapy
Yes N=12, 100%
Number of prior chemotherapy treatments
N (patients) 12
Mean (#prior treatments) 6.5
Std 6.4
Median 5
Min 1
Max 20
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Hospital).
The study was designed to distinguish a favorable true
response rate of 24% from a null rate of 5% using a con-
ventional 2-step phase II study design model [14]. The
first group of 12 subjects was to be enrolled. If no pa-
tient experienced response after all 12 subjects had been
followed for at least 3 months, further accrual would be
stopped and the study drug would be declared as
ineffective. If 1 or more patients experienced response,
an additional 10 patients would be enrolled to a total
s t u d yp o p u l a t i o no fN = 2 2 .I f3o rm o r ep a t i e n t s
among 22 eligible, treated patients experience response,
the drug would be considered effective and worthy of fur-
ther study. Study-wide response rates were to be estimated
after all subjects had been followed for at least 6 months.
This statistical model assumes a null versus alternative
response rate as 5% versus 24%, with a 9% type I error and
91% power. This design had a 54% probability of stopping
early if the drug was ineffective.
Olaparib was administered orally at 400 mg (tablet formu-
lation) twice daily. Participants were to take Olaparib twice
daily, without break, and were supplied a sufficient quantity
on Day 1 of the study to last until the second study visit
( D a y4 3 ) .A f t e rD a y1o ft h es t u d yadditional visits occurred
after 6 weeks, 12 weeks, and then every 8 weeks thereafter.
Subjects were instructed not to make up for vomited doses,
and to record missed or vomited doses on the Patient Diary
Card. Safety and tolerability were monitored continuously
throughout study participation.
Tumor assessments using CT scans of the chest, abdo-
men, and pelvis were done at baseline and then repeated
after 6 weeks, 12 weeks, and then every 8 weeks there-
after to assess disease status.
Table 2 Toxicity maximum grade per patient – attributable
to treatment
Toxicity
type
Description Grade
123
BL101 Anemia 0 0 2
BL999 Blood and lymphatic system
disorders - Other
100
CN108 Fatigue 3 0 0
CN109 Fever 2 0 0
CN121 Non-cardiac chest pain 1 0 0
GI121 Constipation 1 0 0
GI123 Diarrhea 1 0 0
GI124 Dry mouth 2 0 0
GI179 Nausea 2 1 0
GI210 Stomach pain 1 0 0
GI216 Vomiting 3 0 0
GI999 Gastrointestinal
disorders - Other
100
IN171 Urinary tract infection 1 0 0
IV127 Lymphocyte count decreased 0 0 1
IV131 Platelet count decreased 0 1 1
ME999 Metabolism and nutrition
disorders - Other
200
MU112 Generalized muscle weakness 1 0 0
MU999 Musculoskeletal and
connective tissue
disorder - Other
100
NE118 Dysgeusia 1 0 0
NE126 Headache 1 0 0
PU113 Cough 1 0 0
PU999 Respiratory, thoracic and
mediastinal disorders - Other
100
VA102 Flushing 1 0 0
VA104 Hot flashes 1 0 0
TOTAL 29 2 4
Worst grade per patient across all types
Count Percentage
Mild - grade 1 as worst degree 5 45.45%
Moderate - grade 2 as worst degree 1 9.09%
Severe - grade 3 as worst degree 4 36.36%
Life threatening 1 9.09%
Table 3 Summary details
Reason treatment ended:
Progressive disease N=12, 100%
Best response:
Stable disease N=4, 33.33%
Progressive disease N=8, 66.67%
Number of treatment weeks completed
N1 2
Mean 7.9
Std 4.72
Min 4
Max 20
Duration of stable disease (weeks)
N4
Mean 13.03
Std 3.28
Min 10.9
Max 17.9
Progression-free survival: median of 5.7 weeks.
Survival status
Alive N=1, 8.33%
Dead N=11, 91.67%
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events, study drug administration was to be continued
until one of the following criteria applied: Disease pro-
gression by RECIST 1.1, intercurrent illness that pre-
vented further administration of treatment, unacceptable
adverse events, decision of participant to withdraw from
study, general or specific changes in the participant’s
condition that rendered the participant unacceptable for
further treatment in the opinion of the treating investi-
gator, or bone marrow findings consistent with myelo-
dysplastic syndrome/acute myeloid leukemia.
The study was approved by the Dana-Farber/Harvard
Cancer Center Institutional Review Board, and all patients
signed informed consent prior to study registration. This
study was opened to accrual on May 25, 2012, and closed
to accrual on February 25, 2013. All patients were to be
followed for at least 30 days after removal from study or
until death. Participants who were removed from study
for unacceptable adverse events were to be followed until
resolution or stabilization of the adverse event.
Results
Table 1 displays patient demographics and other charac-
teristics at baseline. The median age was 25.5 years
(range 18 to 70 years). 100% of subjects were white, and
10 (83%) were male, while 2 (17%) were female. 9 subjects
(75%) had prior surgical treatment, and 9 subjects (75%)
had prior radiation treatment. The median number of
prior radiation treatments was 1 and the median number
of prior chemotherapy treatments was 5.
Table 2 displays a summary of treatment-related
adverse events (counts by worst grade per patient, and
worst grade per patient across all toxicities). No deaths
were experienced on this study. There was one occur-
rence of a Grade 4 event (patient was hospitalized with a
pneumonia), and 6 occurrences of Grade 3 events (pain,
anemia, lymphocyte count decreased and platelet count
decreased) across all toxicities. The grade 4 event and 2
of the grade 3 events (pain) were not attributed to the
study drugs or procedures by the study investigators. No
patients were taken off study due to an unacceptable
Figure 1 Percent change from baseline in sum of longest diameter of target lesions. Red: Progressive Disease, Green: Progressive
Disease due to development of new metastatic lesions, Blue: Stable Disease. Two patients did not receive post-treatment imaging due
to rapid clinical progression of disease.
Figure 2 Progression free survival.
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toxicity while on study treatment.
Table 3: Sixty-seven percent of the study subjects (N=8)
experienced Progressive Disease as their best response, and
33% of the study subjects (N = 4) experienced Stable
Disease (Figure 1). Response was measured using
RECIST criteria version 1.1. Table 3 illustrates sum-
mary data and shows that the duration of stable dis-
ease had a median value of 11.6 weeks (N =4), with a
minimum value of 10.9 weeks and a maximum value of
17.9 weeks. Progression free-survival had a median of
5.7 weeks (Figure 2). The 90% Confidence Interval for
t h er e s p o n s er a t ei s{ 0-2 2 % } .
Discussion
In summary, 12 participants with metastatic Ewing
sarcoma were enrolled, and all were evaluable. Two cases
of grade 3 anemia, one case of grade 3 thrombocytopenia,
one case of grade 3 decreased lymphocyte count, and one
case of grade 4 other respiratory, thoracic and mediastinal
disorder were observed. Otherwise, no significant or unex-
pected toxicities were observed while participants were
receiving olaparib. There were 0 PR/CR, 4 SD (duration
10.9, 11.4, 11.9, and 17.9 wks), and 8 PD as best response.
Of the participants who experienced SD, 2 had minor
responses (−9.0% and −11.7% by RECIST 1.1, see Figure 1).
Further enrollment was therefore discontinued after in-
terim analysis.
This lack of clinical efficacy is in direct contrast to
preclinical modeling that supported in vitro sensitivity of
Ewing sarcoma cell lines to olaparib [9]. One explan-
ation for this discrepancy is that some cell lines may
have been derived from patient tumor samples that were
not yet chemoresistant, while all participants in this study
had proven relapse or progression after administration of
standard chemotherapeutic agents for Ewing sarcoma.
Several other factors that could explain the disparity in-
clude failure to achieve in vitro levels of olaparib at the
clinical dose, secondary genomic or epigenomic alter-
ations that might have activated other drivers of tumor
cell proliferation that would render the PARP pathway
nonessential, or yet unidentified mediators of PARP-
rescue derived from tumor-environment interactions.
Preclinical work, however, does support potential ac-
tivity of PARP inhibition when combined with alkylating
agents. In fact, although Brenner et al. showed that in
mice xenografts, Ewing sarcoma (RD-ES) cells treated
with 100 mg/kg of olaparib twice a day still demonstrated
tumor growth, albeit significantly slower than untreated
controls [13], in that same report, olaparib combined with
the alkylating agent, temozolomide, yielded exquisite and
durable in vivo tumor response. Such trials combining
PARP inhibition with chemotherapy are currently being
conducted or under development at several sites across
the U.S. and in Europe.
Conclusion
This study is the first report of a prospective phase II
trial to evaluate the safety and efficacy of a PARP inhibi-
tor in patients with Ewing sarcoma. Olaparib tablets
were well tolerated when administered to this small
cohort at the 400 mg BID dose, although the median
duration of dosing was for only 5.7 weeks. However,
no significant responses were seen, and the short
average interval to disease progression underscores the
aggressiveness of this disease.
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